^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD79A mutation + CD79B mutation

    i
    Other names: CD79A, CD79a Molecule, B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain, MB-1, IGA, Membrane-Bound Immunoglobulin-Associated Protein, CD79a Molecule, Immunoglobulin-Associated Alpha, Surface IgM-Associated Protein, MB-1 Membrane Glycoprotein, Ig-Alpha, CD79A Antigen (Immunoglobulin-Associated Alpha), CD79a Antigen (Immunoglobulin-Associated Alpha), CD79a Antigen, MB1, CD79B, B-Cell Antigen Receptor Complex-Associated Protein Beta Chain, CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta, IGB, B29, CD79b Antigen (Immunoglobulin-Associated Beta), CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Antigen, AGM6
    Entrez ID:
    974; 973
    Related biomarkers:
    Expression
    Mutation
    Associations

    News

    Trials
    7ms
    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=302, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TNFA (Tumor Necrosis Factor-Alpha) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD79A (CD79a Molecule) • GSTT1 (Glutathione S-transferase theta 1)
    |
    BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
    11ms
    B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells. (PubMed, Int J Mol Sci)
    We have reviewed the complex role of CD79a/CD79b in multiple aspects of normal B cell biology and how is the normal BCR signaling affected by lymphoid neoplasms associated CD79A/CD79B mutations. We have also summarized important unresolved questions and highlighted issues that remain to be explored for better understanding of CD79a/CD79b-mediated signal transduction and the eventual identification of additional therapeutically targetable BCR signaling vulnerabilities.
    Review • Journal
    |
    CD79B (CD79b Molecule) • CD79A (CD79a Molecule)
    |
    CD79B mutation • CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
    1year
    Molecular diagnostics for vitreoretinal lymphoma (PubMed, Pathologie (Heidelb))
    PVRL, as well as secondary vitreoretinal lymphomas after PCNSL or extracerebral DLBCL, have high mutation frequencies in characteristically mutated genes in PCNSL or MCD/cluster 5 type DLBCL. Supporting diagnostics, mutation detection can also be performed on cell-free DNA from the vitreous supernatant.
    Review • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • CD79A (CD79a Molecule)
    |
    CDKN2A deletion • CDKN2A mutation • CD79B mutation • CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
    1year
    Zanubrutinib Plus Salvage Chemotherapy in Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for Autologous Stem Cell Transplantation: A Retrospective Study (ASH 2023)
    We retrospectively reviewed R/R DLBCL patients who were administered with Zanubrutinib 160mg*bid plus BR (Bendamustine 90mg/㎡*d1-2+Rituximab 375mg/㎡*d0)or R2 (Lenalidomide 25mg* d1-21 +Rituximab 375mg/㎡*d0)in our center between January, 2019 and July, 2023. Zanubrutinib combined with BR or R2 showed promising efficacy and acceptable safety in R/R DLBCL patients, which may be a potential treatment option for autologous stem cell transplantation-ineligible R/R DLBCL patients.
    Retrospective data
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79A (CD79a Molecule)
    |
    TP53 mutation • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib) • bendamustine
    over1year
    ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL (EHA 2023)
    Although preliminary, the responders to the OR induction therapy may attain a synergistic antitumor effect and thus achieve a high CRR when receiving subsequent O+R-CHOP. The safety was favorable. More updated data will be presented from this ongoing study.
    Clinical • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79A (CD79a Molecule)
    |
    TP53 mutation • BCL2 expression • MYC expression • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    almost2years
    Comparative analysis of clinicopathologic features and tumor immune-microenvironment of primary diffuse large B cell lymphoma of the central nervous system according to molecular classification (AACR 2023)
    This is the first reporting molecular classification and their clinical significance in PCNS-DLBCL of Asian population. MCD subtype was prevalent but has no prognostic power in PCNS-DLBCL. Further larger study is needed.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD79B (CD79b Molecule) • CD163 (CD163 Molecule) • BCL7A (BAF Chromatin Remodeling Complex Subunit BCL7A) • CD68 (CD68 Molecule) • CD79A (CD79a Molecule) • FOXP3 (Forkhead Box P3) • MVP (Major Vault Protein)
    |
    PD-L1 expression • TP53 mutation • LDH elevation • CDKN2A deletion • CDKN2A mutation • MYD88 L265P • PD-1 expression • CD79B mutation • CD79B mutation • CD79A mutation • BCL7A mutation • MYD88 L265P + CD79B mutation • CD79A mutation + CD79B mutation
    2years
    Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. (PubMed, J Immunol)
    Rescue experiments with CD79B wild-type restored surface expression of CD79A and IgM with mature glycosylation, whereas a naturally occurring CD79B G137S mutant disrupting CD79A/CD79B heterodimerization did not. Our study highlights that CD79A and CD79B are required for surface IgM expression in human B cells and illuminates the importance of the IgM expression level for signaling and fitness.
    Journal
    |
    CD79B (CD79b Molecule) • CD79A (CD79a Molecule)
    |
    CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
    2years
    Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma (ASH 2022)
    Zanubrutinib (160 mg po bid) plus R-CHOP (ZR-CHOP) was administered in TN cohort, and Zanubrutinib (160 mg po bid) combined with investigator-determined conventional salvage chemotherapy (CSC, including ICE, DHAP, GDP, or GemOx, +/- rituximab) was administered in R/R cohort. CD79A/CD79B mutation was frequent in DLBCL patients, especially in R/R cases. Zanubrutinib combined with immunochemotherapy showed encouraging activity and acceptable tolerance in pts with CD79A/CD79B-mutant DLBCL. TP53 mutation seemed to be a detrimental factor.
    Clinical
    |
    TP53 (Tumor protein P53) • CD79B (CD79b Molecule) • CD79A (CD79a Molecule)
    |
    TP53 mutation • CD79B mutation • CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)